Building upon the successful application of the proteasome inhibitor (PI) Bortezomib (BTZ) in the treatment of multiple myeloma (MM) [7,8,9,10] and some solid tumors [11], BTZ has also been proposed for the treatment of acute leukemia [12,13,14]. Here, CASC3 is linked to Miyoshi myopathy.